Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a biotechnology company with a market capitalization of $1.07 billion, recently executed a series of stock ...

At 37, Melvin Mann began experiencing persistent back pain and fatigue. After undergoing several tests in 1994, doctors diagnosed the Army major with a form of blood cancer called chronic myeloid ...